LSV Asset Management reduced its position in Mylan N.V. (NASDAQ:MYL) by 1.0% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 578,995 shares of the company’s stock after selling 6,100 shares during the period. LSV Asset Management owned 0.11% of Mylan N.V. worth $22,476,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. First Personal Financial Services lifted its holdings in shares of Mylan N.V. by 33.2% in the 1st quarter. First Personal Financial Services now owns 2,733 shares of the company’s stock valued at $107,000 after purchasing an additional 681 shares during the last quarter. Global X Management Co. LLC increased its position in Mylan N.V. by 91.6% in the 1st quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock valued at $118,000 after acquiring an additional 1,441 shares during the period. TLP Group LLC acquired a new position in Mylan N.V. in the 1st quarter valued at about $200,000. Eagle Global Advisors LLC acquired a new position in Mylan N.V. in the 2nd quarter valued at about $205,000. Finally, Clear Harbor Asset Management LLC acquired a new position in Mylan N.V. in the 2nd quarter valued at about $215,000. 71.97% of the stock is owned by institutional investors and hedge funds.

MYL has been the topic of several recent research reports. Barclays PLC upgraded Mylan N.V. from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $47.00 to $50.00 in a research report on Monday, May 22nd. Cantor Fitzgerald initiated coverage on Mylan N.V. in a research report on Friday, June 16th. They issued a “neutral” rating and a $41.00 price target on the stock. Royal Bank Of Canada set a $41.00 price target on Mylan N.V. and gave the company a “hold” rating in a research report on Sunday, July 16th. BidaskClub upgraded Mylan N.V. from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Finally, Wells Fargo & Company restated a “market perform” rating and issued a $40.00 price target on shares of Mylan N.V. in a research report on Wednesday, May 31st. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $43.43.

TRADEMARK VIOLATION WARNING: “LSV Asset Management Trims Stake in Mylan N.V. (MYL)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/13/lsv-asset-management-trims-stake-in-mylan-n-v-myl.html.

Shares of Mylan N.V. (MYL) opened at 33.60 on Wednesday. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87. The stock has a market cap of $18.02 billion, a price-to-earnings ratio of 27.16 and a beta of 1.31. The stock’s 50 day moving average price is $32.99 and its 200 day moving average price is $37.78.

Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.18 by ($0.08). Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The firm had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3 billion. During the same quarter in the previous year, the business posted $1.16 EPS. Mylan N.V.’s revenue for the quarter was up 15.7% compared to the same quarter last year. Equities research analysts anticipate that Mylan N.V. will post $4.52 EPS for the current fiscal year.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan N.V. (NASDAQ:MYL)

Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.